StreetInsider.com News Articles

Passage Bio terminates collaboration deal, exits office lease

Wed, 27 May 2026 16:19:58 -0400

Passage Bio Inc. (NASDAQ: PASG) terminated its research collaboration agreement with Gemma Biotherapeutics Inc., providing written notice on May 21, 2026, according to a company statement.

The collaboration agreement, originally signed on July 31, 2024, involved Gemma conducting preclinical and Investigational New Drug-enabling work for Passage Bio's Huntington's disease research program and a paused Temporal Lobe Epilepsy program. Gemma had also granted Passage Bio options to conduct research programs in four central nervous system indications.

Separately, Passage Bio agreed to terminate its office lease at 2005 Market Street in Philadelphia, paying a $2.3 million termination fee to landlord Commerce Square Partners –

Form 8-K Passage BIO, Inc. For: May 21

Wed, 27 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260527/26558080.html

Form 8-K Passage BIO, Inc. For: May 21

Wed, 27 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260527/26558080.html

Form 8-K Passage BIO, Inc. For: May 19

Tue, 26 May 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260526/26545794.html

Form 8-K Passage BIO, Inc. For: May 19

Tue, 26 May 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260526/26545794.html

Form 4 Passage BIO, Inc. For: May 19 Filed by: Porter Derrell

Thu, 21 May 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260521/26535454.html

Form 4 Passage BIO, Inc. For: May 19 Filed by: Porter Derrell

Thu, 21 May 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260521/26535454.html

Form 4 Passage BIO, Inc. For: May 19 Filed by: Sondhi Dolan

Thu, 21 May 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260521/26535464.html

Form 4 Passage BIO, Inc. For: May 19 Filed by: Sondhi Dolan

Thu, 21 May 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260521/26535464.html

Form 4 Passage BIO, Inc. For: May 19 Filed by: Kassberg Thomas Richard

Thu, 21 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260521/26535441.html

Form 4 Passage BIO, Inc. For: May 19 Filed by: Kassberg Thomas Richard

Thu, 21 May 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260521/26535441.html

Form 4 Passage BIO, Inc. For: May 19 Filed by: Kapadia Sandip

Thu, 21 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260521/26535423.html

Form 4 Passage BIO, Inc. For: May 19 Filed by: Kapadia Sandip

Thu, 21 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260521/26535423.html

Form 4 Passage BIO, Inc. For: May 19 Filed by: Countouriotis Athena

Thu, 21 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260521/26535374.html

Form 4 Passage BIO, Inc. For: May 19 Filed by: Countouriotis Athena

Thu, 21 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260521/26535374.html

Form 4 Passage BIO, Inc. For: May 19 Filed by: GOWEN MAXINE

Thu, 21 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260521/26535398.html

Form 4 Passage BIO, Inc. For: May 19 Filed by: GOWEN MAXINE

Thu, 21 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260521/26535398.html

Form 10-Q Passage BIO, Inc. For: Mar 31

Tue, 12 May 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260512/26472841.html

Form 10-Q Passage BIO, Inc. For: Mar 31

Tue, 12 May 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260512/26472841.html

Form 8-K Passage BIO, Inc. For: Apr 28

Tue, 28 Apr 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260428/26378161.html

Form 8-K Passage BIO, Inc. For: Apr 28

Tue, 28 Apr 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260428/26378161.html

TD Cowen Downgrades Passage Bio Inc. (PASG) to Hold

Tue, 21 Apr 2026 09:04:43 -0400

TD Cowen analyst Brendan Smith downgraded Passage Bio Inc. (NASDAQ: PASG) from Buy to Hold.

The analyst comments "PASG released updated Ph1/2 FTD-GRN data in line with prior updates but also confirmed FDA will require a randomized, placebo-controlled registrational study for PBFT02, removing a potentially expedited path to market in FTD-GRN. We are downgrading shares of PASG to Hold as the future of PBFT02 remains uncertain and mgmt pursues strategic alternatives to maximizing shareholder value."

For an analyst ratings summary and ratings history on Passage Bio Inc. click here. For more ratings news on Passage Bio Inc. click here.

Shares of

TD Cowen Downgrades Passage Bio Inc. (PASG) to Hold

Tue, 21 Apr 2026 09:04:43 -0400

TD Cowen analyst Brendan Smith downgraded Passage Bio Inc. (NASDAQ: PASG) from Buy to Hold.

For an analyst ratings summary and ratings history on Passage Bio Inc. click here. For more ratings news on Passage Bio Inc. click here.

Shares of

Passage Bio Inc. (PASG) PT Lowered to $15 at Oppenheimer

Tue, 21 Apr 2026 07:06:19 -0400

(Updated - April 21, 2026 7:06 AM EDT)

Oppenheimer analyst Jay Olson lowered the price target on Passage Bio Inc. (NASDAQ: PASG) to $15.00 (from $30.00) while maintaining a Outperform rating.

The analyst commented: "On 4/20, PASG released upliFT-D data alongside FDA feedback. This update was mixed: 1) we believe the clinical dataset actually supports continued exploration of PFBT02, especially in milder patients, given brain atrophy slowing and NfL reduction for those patients with CDR+NACC FTLD of 1; and 2) recognizing small sample size, lower Dose 2 elicited CSF PRGN on par with higher Dose 1, while maintaining a DRG tox-free profile

Passage Bio Inc. (PASG) PT Lowered to $15 at Oppenheimer

Tue, 21 Apr 2026 07:06:19 -0400

(Updated - April 21, 2026 7:06 AM EDT)

Oppenheimer analyst Jay Olson lowered the price target on Passage Bio Inc. (NASDAQ: PASG) to $15.00 (from $30.00) while maintaining a Outperform rating.